Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an announcement.
Clarity Pharmaceuticals Ltd announced the cessation of 87,858 securities due to the lapse of conditional rights, as the conditions for these securities have not been met or have become incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational and strategic direction.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$7.40 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is engaged in creating innovative therapies that leverage its proprietary technology to target specific cancer cells.
Average Trading Volume: 2,906,295
Technical Sentiment Signal: Hold
Current Market Cap: A$908.8M
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.